Answers are grounded in this paper and cite their sources.
We have devised a molecular-to-micellar strategy to incorporate a lanthanide nanoplatform for the delivery of an anticancer drug that simultaneously offers hybrid near-infrared (NIR) and magnetic resonance imaging (MRI) capabilities with defined lanthanide(III) ratio control. This cancer-selective lanthanide-based self-assembled nanocomposite ( LnNPs ) has been synthesized by conjugating lanthanide–cyclen complexes ( cycLn ) with a well-known drug–camptothecin ( CPT ) through a redox-sensitive disulfide bond (− ss– ). By accurately controlling the ratio of Gd(III) and Yb(III) complexes, we prepared hybrid nanoparticles ( Gd/YbNPs ) with both NIR and MR imaging properties. The enhanced stability at ultralow critical aggregation concentrations (CACs), simultaneous optical and MR imaging, improved delivery/chemotherapeutic efficiency, and cancer cell selectivity of such nanomicellar theranostic prodrugs in vitro and in vivo have thus been achieved and validated. The work provides a blueprint combining a stimuli-activated NIR luminescence and real-time MR imaging into a safe and biocompatible nanoplatform for selective cancer treatment.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: